QI
ESPR

QS Investors’s Esperion Therapeutics ESPR Stock Holding History

QS Investors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-12,150
Closed -$452K – 1211
2020
Q3 		$452K Sell
12,150
-50,000
-80% -$1.98M 0.01% 741
2020
Q2 		$3.19M Hold
62,150
– – 0.04% 327
2020
Q1 		$1.96M Hold
62,150
– – 0.03% 418
2019
Q4 		$3.81M Sell
62,150
-985
-2% -$44.3K 0.04% 361
2019
Q3 		$2.31M Hold
63,135
– – 0.03% 519
2019
Q2 		$2.94M Buy
63,135
+13,135
+26% +$617K 0.03% 444
2019
Q1 		$2.01M Buy
+50,000
New +$2.24M 0.02% 606

Other funds holding ESPR

BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

QS Investors's ESPR Position: Q4 2020 in Review

QS Investors sold out of Esperion Therapeutics (ESPR) in Q4 2020, closing a stake of 12,150 shares — an estimated $452K sold.

QS Investors first reported a position in ESPR in Q1 2019 and held it in 7 quarters. The position peaked at $3.81M in Q4 2019. 157 funds tracked by Wall St. Rank hold ESPR as of Q4 2020.

  • QS Investors reported no remaining Esperion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • QS Investors sold 12,150 Esperion Therapeutics shares in Q4 2020, an estimated $452K.
  • QS Investors first reported a position in Esperion Therapeutics in Q1 2019 and held it in 7 quarters.
  • QS Investors's Esperion Therapeutics position peaked at $3.81M in Q4 2019.
  • 157 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q4 2020.

Based on QS Investors's 13F filing for Q4 2020, filed 10 Feb 2021.